

The Board of Pharmacy has received notice of the following product recall. The Board strongly encourages pharmacies to immediately review their quality assurance and recall policies and procedures to determine if any corrective action is required.

Description	Lot #	Exp Date	NDC	UPC
MPB BDI PRIVIGEN 5GM 50ML	P100287718	11/15/2023		
MPB PRIVIGEN 5GM 50ML	P100287718	11/15/2023	44206043605	34420643605
MPB PRIVIGEN 5GM 50ML EMRY	P100287718	11/15/2023		
BRDLN PRIVIGEN 20GM VL DS CSL	P100356115	07/05/2024	44206043820	34420643820
MPB PRIVIGEN 20GM 200ML	P100356115	07/05/2024		
BRDLN PRIVIGEN 40GM VL DS	P100371288	08/20/2024	44206043940	34420643940
	P100366291	08/19/2024		
MPB BDI PRIVIGEN 40GM 400ML	P100371288	08/20/2024	44206043940	34420643940
	P100366291	08/19/2024		
MPB PRIVIGEN 40GM 400ML	P100371288	08/20/2024	44206043940	34420643940
	P100366291	08/19/2024		

CSL Behring is withdrawing the above items/lots due to an increased frequency of reports of injection-site reactions and local hypersensitivity-type of events after administration. This withdrawal is to the retail level. Affected product started shipping November 16, 2021.